Q3 2025 Neogenomics Inc Earnings Call Transcript
Key Points
- NeoGenomics Inc (NEO) delivered record clinical volumes and revenues in Q3 2025, with total revenue reaching $188 million, a 12% year-over-year increase.
- The company achieved a 24% growth in NGS revenue, significantly outpacing the market growth rate, driven by the successful launch of five NGS products in 2023.
- NeoGenomics Inc (NEO) secured a favorable court ruling in its litigation with Natera, allowing for the full clinical launch of its RaDaR ST MRD assay.
- The acquisition of Pathline has expanded NeoGenomics Inc (NEO)'s presence in the Northeast, the third-largest cancer care market in the US, and is expected to enhance growth and profitability starting in 2026.
- The company has a strong balance sheet with $164 million in cash, enabling continued investment in business growth and operational efficiencies.
- Nonclinical revenue declined in Q3 2025 due to lower revenue from pharma and biotech customers, accounting for less than 9% of total revenue.
- NeoGenomics Inc (NEO) recorded an additional $7 million in impairment charges related to the planned sale of Trapelo, contributing to increased operating expenses.
- The company anticipates continued softness in its pharma business throughout 2026, with a return to growth expected in 2027.
- Despite the launch of PanTracer LBx, reimbursement for the liquid biopsy test is still pending, which could delay revenue recognition.
- NeoGenomics Inc (NEO) reported a net loss for the full year 2025, expected to be in the range of $116 million to $108 million, an increase compared to the previous year.
Good morning, everyone, and welcome to the NeoGenomics Third Quarter 2025 Financial Results Call. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the conference over to your host, Priya Vedaraman, Senior Vice President of Finance at NeoGenomics. The floor is yours.
Thank you, Jenny, and good morning, everyone. Welcome to the NeoGenomics Third Quarter 2025 Financial Results Call. With me today to discuss the results are Tony Zook, Chief Executive Officer; and Jeff Sherman, Chief Financial Officer. Additional members of the management team will be available for the Q&A portion of our call.
This call is being simultaneously webcast. For reference, concurrent with today's call, we posted a short slide presentation in the Investor tab on our website at ir.neogenomics.com. During this call, we will make forward-looking statements regarding our future financial and business performance, business strategy, the timing and outcome of reimbursement
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
